Stock VRTX VERTEX PHARMACEUTICALS INCORPORATED
Add to a list
To use this feature you must be a member
Log inSign up

Consensus Vertex Pharmaceuticals Incorporated

Equities

VRTX

US92532F1003

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-06-06 pm EDT 		5-day change 1st Jan Change
485.5 USD +0.52% Intraday chart for Vertex Pharmaceuticals Incorporated +9.59% +19.33%
Jun. 05 Vertex Pharmaceuticals Insider Sold Shares Worth $1,495,000, According to a Recent SEC Filing MT
Jun. 05 Vertex Pharmaceuticals Insider Sold Shares Worth $1,000,500, According to a Recent SEC Filing MT

Evolution of the average Target Price on Vertex Pharmaceuticals Incorporated

Price target over the last 5 years

History of analyst recommendation changes

846278f00ab3e6d53c.0WQxvtlGbplNglbdUR4oAuKzW7blaG5YMZtcqv3EFwI.4Ql0h64gJaAk5DuCfFR_NonqHoafL1wvUsoDybSxWHajNHWMiQtfyQT0MQ~c52d45e51dd6cb67d877a109a8acdf77

Analyst Recommendations on Vertex Pharmaceuticals Incorporated

Vertex Pharmaceuticals Insider Sold Shares Worth $1,000,500, According to a Recent SEC Filing MT
Vertex Pharmaceuticals Insider Sold Shares Worth $2,033,159, According to a Recent SEC Filing MT
BMO Capital Adjusts Price Target on Vertex Pharmaceuticals to $500 From $480 MT
Vertex Pharmaceuticals Insider Sold Shares Worth $1,478,068, According to a Recent SEC Filing MT
Vertex Pharmaceuticals Insider Sold Shares Worth $715,205, According to a Recent SEC Filing MT
Vertex Pharmaceuticals Insider Sold Shares Worth $3,168,704, According to a Recent SEC Filing MT
Vertex Pharmaceuticals Insider Sold Shares Worth $6,795,294, According to a Recent SEC Filing MT
Wolfe Research Adjusts Price Target on Vertex Pharmaceuticals to $520 From $497 MT
ANALYST RECOMMENDATIONS : Nvidia, The Home Depot, Lowe's, Rollins... Our Logo
Leerink Partners Adjusts Vertex Pharmaceuticals' Price Target to $529 From $511 MT
Stifel Adjusts Vertex Pharmaceuticals' Price Target to $420 From $430 MT
Piper Sandler Adjusts Price Target on Vertex Pharmaceuticals to $456 From $450, Keeps Overweight Rating MT
Morgan Stanley Adjusts Price Target on Vertex Pharmaceuticals to $402 From $413, Keeps Equalweight Rating MT
RBC Adjusts Price Target on Vertex Pharmaceuticals to $424 From $417, Keeps Sector Perform Rating MT
Goldman Sachs Adjusts Price Target on Vertex Pharmaceuticals to $577 From $574, Keeps Buy Rating MT
Bernstein Adjusts Price Target on Vertex Pharmaceuticals to $458 From $450, Keeps Market Perform Rating MT
Wolfe Research Adjusts Price Target on Vertex Pharmaceuticals to $497 From $515 MT
UBS Adjusts Vertex Pharmaceuticals Price Target to $466 From $498, Maintains Buy Rating MT
Guggenheim Adjusts Vertex Pharmaceuticals' Price Target to $450 From $445 MT
Western Drugmakers Seeking Alternative Suppliers as US Looks to Restrict Chinese Biotech MT
Western Drugmakers Seeking Alternative Suppliers as US Looks to Restrict Chinese Biotech MT
HC Wainwright Raises Vertex Pharmaceuticals' Price Target to $462 From $457, Maintains Buy Rating MT
Wedbush Downgrades Alpine Immune Sciences to Neutral From Outperform, Raises Price Target to $65 From $47, Expects Vertex Deal to Close MT
Evercore ISI Upgrades Vertex Pharmaceuticals to Outperform From In Line MT
RBC Downgrades Alpine Immune Sciences to Sector Perform From Outperform, Removes Speculative Risk, Lifts Price Target to $65 From $41 Amid Vertex Deal MT
More recommendations

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
31
Last Close Price
485.5 USD
Average target price
463.5 USD
Spread / Average Target
-4.53%
High Price Target
577 USD
Spread / Highest target
+18.84%
Low Price Target
325 USD
Spread / Lowest Target
-33.06%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Vertex Pharmaceuticals Incorporated

BMO Capital
Wolfe Research
Leerink Partners
Stifel Nicolaus
Goldman Sachs
Bernstein
RBC Capital Markets
Morgan Stanley
Piper Sandler
UBS
Guggenheim
HC Wainwright
Evercore ISI
Wells Fargo Securities
Jefferies & Co.
JPMorgan Chase
Barclays
Maxim
Oppenheimer
BofA Securities
Cantor Fitzgerald
Canaccord Genuity
TD Cowen
Truist Securities
Baird
SVB Securities LLC
Argus
Cowen
SVB Leerink
Raymond James
Citigroup
Daiwa Securities
Credit Suisse

Ratings for Vertex Pharmaceuticals Incorporated

Trading Rating
Investor Rating
ESG Refinitiv
B+
More Ratings

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar
  1. Stock Market
  2. Equities
  3. VRTX Stock
  4. Consensus Vertex Pharmaceuticals Incorporated